In 2008, the American Society of Clinical Oncology commissioned a report that declared that the partial type of genetic analysis offered by 23andMe had not been clinically proved to be effective in cancer care. Two years later, the US Government Accountability Office concluded after a lengthy investigation that DTC genetic tests provide “misleading” results – a situation that is complicated further by “deceptive marketing.”
对23andMe公司的PGS的质疑由来已久。2008年，美国临床肿瘤协会（American Society of Clinical Oncology）发布了一份委员会报告，称23andMe公司所提供的局部类型遗传分析在临床上并不是有效的癌症疗法。两年后，美国政府问责办公室（US Government Accountability Office）在经过长期的调查后认定DTC遗传测试提供了“误导性”结果——而“欺骗性营销”让这一局面更加复杂了。